1. Show article details.

    A Plan to Fight Hep C -- WSJ

    DJ Business News – 2:47 AM ET 09/16/2019

    Louisiana is a testing ground for a new payment model that may help states provide life-saving medicine for everybody who needs them By Ted Alcorn. This article is being republished as part of our daily reproduction of WSJ.com articles that also appeared in the U.S. print edition of The Wall Street Journal. The crowd at the New Orleans health clinic in late June filled the seats and overflowed into the wings.

  2. Show article details.

    Advances in Biotechnology May Offer Cancer Patients Renewed Hope

    PR Newswire – 9:00 AM ET 09/10/2019

    NEW YORK, Sept. 10, 2019 The biotechnology market is currently one of the largest industries in the world. The cancer treatment market is one of the biggest segments of the biotechnology industry.

  3. Show article details.

    BRIEF-Gilead Sciences And The Elton John Aids Foundation Launch Radian Initiative

    Reuters – 7:53 AM ET 09/09/2019

    Gilead Sciences Inc (GILD): * GILEAD SCIENCES AND THE ELTON JOHN AIDS FOUNDATION LAUNCH RADIAN INITIATIVE TO ADDRESS HIV IN EASTERN EUROPE AND CENTRAL ASIA Source text for Eikon: Further company coverage:

  4. Show article details.

    Gilead Sciences and the Elton John AIDS Foundation Launch RADIAN Initiative to Address HIV in Eastern Europe and Central Asia (EECA)

    Business Wire – 7:30 AM ET 09/09/2019

    -- Initiative to Provide Support to Local Organizations Working to Positively Impact the Lives of People Affected by and at Risk of HIV -- Gilead Sciences, Inc. (GILD) and the Elton John AIDS Foundation today announced the launch of the ground-breaking RADIAN initiative at the Fast-Track Cities 2019 conference in London. This press release features multimedia.

  5. Show article details.

    BRIEF-Japan Tobacco Inc - Transfer Date Of Marketing Approvals Of 6 Anti-Hiv Drugs To Gilead Sciences Kk Set For Dec. 1

    Reuters – 2:02 AM ET 09/02/2019

    Japan Tobacco Inc (JAPAF): * Japan Tobacco Inc (JAPAF) - TRANSFER DATE OF MARKETING APPROVALS OF 6 ANTI-HIV DRUGS TO GILEAD SCIENCES KK SET FOR DEC. 1 Source text for Eikon: Further company coverage:

  6. Show article details.

    FDA flags risks from AbbVie, Gilead, Merck hepatitis C drugs to certain patients

    Reuters – 3:45 PM ET 08/28/2019

    The U.S. Food and Drug Administration said on Wednesday it had identified 63 cases of worsening liver function in certain patients taking hepatitis C medicines made by drugmakers Merck & Co Inc (MRK), Gilead Sciences (GILD) and AbbVie Inc. The agency said that while the treatments are safe and effective, it had received reports of rare but serious instances of worsening liver function or failure when they w...

  7. Show article details.

    FDA flags serious risks with hepatitis C drugs from AbbVie, Gilead and Merck

    Reuters – 3:25 PM ET 08/28/2019

    The U.S. Food and Drug Administration said on Wednesday it had identified 63 cases of worsening liver function in certain patients taking hepatitis C medicines made by drugmakers Merck & Co Inc (MRK), Gilead Sciences (GILD) and AbbVie Inc. The agency said that while the treatments are safe and effective, it had received reports of rare but serious instances of worsening liver function or failure when these ...

  8. Show article details.

    BRIEF-FDA Warns Patients, Health Care Professionals About Rare Instances Of Serious Liver Injury In Some Patients With Advanced Liver Disease

    Reuters – 3:18 PM ET 08/28/2019

    Abbvie Inc (ABBV): * FDA IN BRIEF: FDA WARNS PATIENTS AND HEALTH CARE PROFESSIONALS ABOUT RARE INSTANCES OF SERIOUS LIVER INJURY OR FAILURE WITH CERTAIN HEPATITIS C TREATMENTS IN SOME PATIENTS WITH ADVANCED LIVER DISEASE. * FDA - GOT REPORTS THAT USE OF MAVYRET, ZEPATIER, VOSEVI FOR CHRONIC HEPATITIS C RESULTED IN RARE CASES OF WORSENING LIVER FUNCTION, LIVER FAILURE.

  9. Show article details.

    Gilead Sciences to Present at the Morgan Stanley Global Healthcare Conference on Tuesday, September 10

    Business Wire – 4:34 PM ET 08/26/2019

    Webcast Available Through Gilead Corporate Website Gilead Sciences, Inc. (GILD) today announced that Daniel O’Day, Gilead’s Chairman and Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference in New York on Tuesday, September 10 at 10:00 a.m. Eastern Time.

  10. Show article details.

    BRIEF-Alberta Provides Access To Biktarvy For The Treatment Of Hiv

    Reuters – 3:53 PM ET 08/26/2019

    Gilead Sciences Inc (GILD): * ALBERTA PROVIDES ACCESS TO BIKTARVY® FOR THE TREATMENT OF HIV. * GILEAD SCIENCES CANADA - EFFECTIVE AUG 22, PROVINCE OF ALBERTA WILL PROVIDE ELIGIBLE PATIENTS WITH ACCESS TO BIKTARVY TABLETS Source text for Eikon: Further company coverage:

  11. Show article details.

    Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration

    Business Wire – 4:01 PM ET 08/23/2019

    Gilead Sciences, Inc. (GILD) and Galapagos NV (GLPG) today announced the closing of the global research and development collaboration agreement signed on July 14, 2019. This press release features multimedia.

  12. Show article details.

    GSK's long acting HIV injection gets boost from study

    Reuters – 3:28 AM ET 08/22/2019

    * 2-month injection as effective as once a month. * Part of GSK effort to score with 2-drug combinations. * GSK up against competition from Gilead's 3-drug combo. By Ludwig Burger and Pushkala Aripaka.

  13. Show article details.

    European Medicines Agency Validates Marketing Application for Filgotinib for the Treatment of Rheumatoid Arthritis

    Business Wire – 4:01 PM ET 08/15/2019

    Gilead Sciences, Inc. (GILD) and Galapagos NV (GLPG) today announced that the Marketing Authorization Application for filgotinib, an investigational, oral, selective JAK1 inhibitor, for the treatment of adults with rheumatoid arthritis has been validated and is now under evaluation by the European Medicines Agency. This press release features multimedia.

  14. Show article details.

    BRIEF-Québec Provides Access to Biktarvy for the Treatment of HIV

    Reuters – 8:30 AM ET 08/15/2019

    Gilead Sciences Inc (GILD): * GILEAD SCIENCES CANADA - QUÉBEC PUBLIC DRUG INSURANCE PLAN WILL PROVIDE ELIGIBLE PATIENTS WITH ACCESS TO BIKTARVY TABLETS. * GILEAD SCIENCES CANADA - QUÉBEC PUBLIC DRUG INSURANCE PLAN WILL PROVIDE ELIGIBLE PATIENTS WITH ACCESS TO COMPLETE REGIMEN FOR TREATMENT OF HIV-1 INFECTION IN ADULTS Source text for Eikon: Further company coverage:

  15. Show article details.

    Ebola "no longer incurable" as Congo trial finds drugs boost survival

    Reuters – 7:37 AM ET 08/13/2019

    * Clinical trial switches focus to two promising treatments. * Results described as "very good news" in Ebola fight. * Year-long Congo outbreak has killed at 1,800 people. * Antibody-based drugs improved survival rates in trial. By Kate Kelland.

  16. Show article details.

    Scientists hail promise of first effective Ebola treatments in Congo trial

    Reuters – 11:17 AM ET 08/12/2019

    * Clinical trial switches focus to two promising treatments. * Results described as "very good news" in Ebola fight. * Year-long Congo outbreak has killed at 1,800 people. * Antibody-based drugs improved survival rates in trial. By Kate Kelland.

  17. Show article details.

    Congo trial of Ebola treatments switches to focus on two drugs

    Reuters – 10:29 AM ET 08/12/2019

    A clinical trial of four potential Ebola treatments in Congo has been narrowed to focus on two of the experimental drugs - Regeneron's REGN-EB3 and a monoclonal antibody called mAb114 - after they showed encouraging results, scientists leading the trial said on Monday.

  18. Show article details.

    Gilead's HIV drug Biktarvy approved in China

    MarketWatch – 9:00 AM ET 08/09/2019

    Gilead Sciences Inc.' s drug Biktarvy has been approved for the treatment of HIV-1 in China, the company said Friday. The China National Medical Products Administration approved the drug as a treatment for patients with HIV-1 that isn't resistant to the integrase inhibitor class of drugs, emtricitabine or tenofovir. Biktarvy received marketing approval from the U.S.

  19. Show article details.

    China National Medical Products Administration Approves Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection

    Business Wire – 8:30 AM ET 08/09/2019

    -- Biktarvy demonstrated high efficacy and a high barrier to resistance in clinical trials through 48 weeks -- Gilead Sciences, Inc. (GILD) announced today that the China National Medical Products Administration has approved Biktarvy®, a once-daily single tablet regimen for the treatment of HIV-1 infection.

  20. Show article details.

    Medicare Moves to Cover Costly Cell Therapies

    DJ Business News – 9:23 PM ET 08/07/2019

    Medicare and Medicaid will cover an expensive new kind of cancer drug and related services, though the federal government insurance programs won't pay 100% of the costs, which can approach $1 million a patient. The move, announced Wednesday by the Centers for Medicare and Medicaid Services, could pave the way for more patients to get the cancer drugs, known as CAR-T treatments because hospitals will know they can get payments covering some if not all of the costs.

Page:

Today's and Upcoming Events

  • Oct
    23

    GILD to announce Q3 earnings (Unconfirmed)

Past Events (last 90 days)

  • Sep
    12

    GILD ex-Dividend for $0.63 on 09/12/2019

    • Announce Date: 07/30/2019
    • Record Date: 09/13/2019
    • Pay Date: 09/27/2019
  • Jul
    30

    GILD announced Q2 earnings.

Data provided by Thomson Reuters © 2019

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.